Irma Bisceglia

10PUBLICATIONS
34CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 12, 2026
Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

|May 04, 2026
SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

|Feb 27, 2026
Management of Implantable Cardiovascular Devices in Patients Undergoing Radiotherapy.

Martina Nesti, Maria Laura Canale, Stefano Oliva

|Sep 27, 2025
Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore.

Andrea Camerini, Alessandro Inno, Maria Laura Canale

|Jul 29, 2025
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia

|Apr 14, 2025
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia

Pageof 2

Frequent Collaborators

7 joint publications

Massimiliano Berretta

7 joint publications

Domenico Gabrielli

7 joint publications

Nicola Maurea

6 joint publications

Alessandro Inno